No abstract

No abstract

Data suggest that activated TFH and plasma cells may contribute to the pathogenesis of MN.

Glioblastoma multiforme (GBM) is the most malignant primary tumour of the nervous system (CNS), with a very poor prognosis. The progression-free survival of patients with this condition after diagnosis is 6.2-7.5 months; the median survival is 14.6-16.7 months [1][2][3] and the 5-year survival rate is only 10%. 4 The current standard therapy for GBM is the maximal surgical resection with postoperative

The stimuli-responsive polymer-based platform for controlled drug delivery has gained increasing attention in treating hepatocellular carcinoma (HCC) owing to the fascinating biocompatibility and biodegradability, improved antitumor efficacy, and negligible side effects recently. Herein, a disulfide bond-contained polypeptide nanogel, methoxy poly(ethylene glycol)−poly(l-phenylalanine-co-l-cystine) [mPEG−P(LP-co-LC)] nanogel, which could be responsive to the intracellular reduction microenvironments, was developed to deliver lenvatinib (LEN), an inhibitor of multiple receptor tyrosine kinases, for HCC therapy. The lenvatinib-loaded nanogel (NG/LEN) displayed concise drug delivery under the stimulus of glutathione in the cancer cells. Furthermore, the intracellular reduction-responsive nanomedicine NG/LEN showed excellent antitumor effect and almost no side effects toward both subcutaneous and orthotopic HCC tumor-allografted mice in comparison to free drug. The excellent tumor-inhibition efficacy with negligible side effects demonstrated the potential of NG/LEN for clinical molecular targeted therapy of gastrointestinal carcinoma in the future.

No abstract